InsidersTradesSigma
Declaraciones totales
Empresas
▲ Compras (0 oper.)
▼ Ventas (0 oper.)
Historial del iniciado
Director GeneralCompras declaradas
0
Ventas declaradas
0
Todavía no hay suficientes señales de compra con un horizonte T+90 consolidado para medir un historial.
Historial de señales
Explore the detailed record of transactions filed by Protopapas Anna, Presidente y Director General. Director active across 4 companies, notably Dicerna Pharmaceuticals Inc. In total, 16 reports have been published. History available since 20 May 2022. The latest transaction was filed on 15 July 2026 (U). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Protopapas Anna
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declaraciones16 en total
3444 títulosClass A Common Stock - Restricted Stock UnitsSEC:0001193125-26-305052:1
5146 títulos@ 124,00 US$0.0065% mcap92.9% de su flujoClass A Common StockSEC:0001193125-26-305052:0
6721 títulosCommon StockSEC:0001104659-26-001374:0
2647 títulos0Class A Common StockSEC:0000950170-25-088549:0
21.250 títulos0Common StockSEC:0001104659-25-004596:0
16.750 títulos0Common StockSEC:0001104659-25-004187:0
31.250 títulos0Common StockSEC:0001104659-25-003881:0
2499 títulos0Class A Common StockSEC:0000950170-24-073656:0
31.250 títulos0Common StockSEC:0001104659-24-004551:0
5000 títulos@ 9,36 US$100.0% de su flujoClass A Common StockSEC:0001209191-23-059368:0
16.643 títulos0Common StockSEC:0001104659-23-100443:0
240.244 títulos0Common StockSEC:0001104659-23-004744:0
38.958 títulosCommon StockSEC:0001104659-22-005548:0
100.000 títulosCommon StockSEC:0001104659-21-093665:0
3333 títulosCommon StockSEC:0001399529-21-000107:0
23.902 títulosCommon StockSEC:0001127602-16-039337:0
16 de 16 declaraciones
About Protopapas Anna
Protopapas Anna is Président-Directeur Général. She has 16 filings in total. In the 16 recent filings we hold, the period runs from 2016-02-03 to 2026-07-15, with the most frequent transaction nature listed as Levée d'options. The companies mentioned are Mersana Therapeutics, Inc., Nuvalent, Inc., Dicerna Pharmaceuticals Inc and ARIAD PHARMACEUTICALS INC.
